Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Arvinas announced it has joined The Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) program and Parkinson's Precision Medicine Initiative (PPMI) to advance ARV-102, its investigational PROTAC drug targeting LRRK2 for treating Parkinson's disease and progressive supranuclear palsy. The company plans to initiate Phase 1b and potentially Phase 2 registrational trials in PSP patients in the second half of 2026.

06/04/2026, 8:00 AM • GlobeNewswire

ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight

The ESR1-mutated metastatic breast cancer market is projected to grow at 9.6% CAGR through 2036, driven by rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and adoption of precision oncology. Novel oral SERDs and targeted agents from major pharmaceutical companies are reshaping the treatment landscape. The market was valued at USD 1.5 billion in 2025, with the US representing the largest market share. Recent FDA approvals include VEPPANU (vepdegestrant), the first PROTAC therapy, while several emerging therapies are in clinical development.

05/20/2026, 1:00 PM • GlobeNewswire

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Pharmaceuticals announced an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an oral PROTAC drug for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. Rigel will contribute up to $40 million toward development over four years and pursue U.S. and global commercialization rights. The drug received FDA approval in May 2026, showing a 43% reduction in disease progression or death risk compared to fulvestrant in the Phase 3 VERITAC-2 trial.

05/12/2026, 2:38 PM • Benzinga

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

Arvinas, Inc. announced FDA approval of VEPPANU (vepdegestrant), the first-and-only FDA-approved PROTAC protein degrader, for treating estrogen receptor-positive advanced breast cancer with ESR1 mutations. The approval came ahead of the FDA-assigned PDUFA date of June 5, 2026. The company also reported positive Phase 1 data for ARV-102 showing greater than 50% LRRK2 degradation in Parkinson's disease patients.

05/05/2026, 7:00 AM • GlobeNewswire

Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy

The FDA approved VEPPANU (vepdegestrant), a first-of-its-kind PROTAC therapy developed by Pfizer and Arvinas for treating advanced breast cancer with ESR1 mutations. The Phase 3 VERITAC-2 trial showed vepdegestrant reduced disease progression risk by 43% compared to fulvestrant, with median PFS of 5 months versus 2.1 months. Guardant Health's Guardant360 CDx was also approved as a companion diagnostic for patient identification.

05/04/2026, 12:30 PM • Benzinga

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Arvinas and Pfizer announced FDA approval of VEPPANU (vepdegestrant), the first-ever approved PROTAC protein degrader, for treating ESR1-mutated ER+/HER2- advanced breast cancer. The approval was granted ahead of schedule, based on Phase 3 VERITAC-2 trial data showing vepdegestrant reduced disease progression risk by 43% compared to fulvestrant. The companies plan to select a third-party partner for commercialization.

05/01/2026, 12:43 PM • GlobeNewswire

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Arvinas announced it will present Phase 1 clinical trial data for ARV-102, a PROTAC degrader targeting LRRK2, at the AD/PD 2026 conference in Copenhagen on March 18, 2026. The presentation will highlight safety, pharmacokinetic, and pharmacodynamic data from participants with Parkinson's disease. The company plans to initiate a Phase 1b trial in progressive supranuclear palsy patients in the first half of 2026, pending regulatory approval.

03/11/2026, 7:00 AM • GlobeNewswire

New nanoparticle technology offers hope for hard-to-treat diseases

Researchers at University of Technology Sydney have developed nanoparticle-mediated targeting chimeras (NPTACs), a new technology that can degrade disease-causing proteins to treat conditions like dementia, brain cancer, and autoimmune disorders. The technology overcomes limitations of conventional targeted protein degradation tools and has shown strong preclinical results. The targeted protein degradation market is expected to exceed $10 billion USD by 2030.

01/21/2026, 11:12 PM • GlobeNewswire

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Arvinas presented preclinical data showing enhanced antitumor activity when combining ARV-393 and glofitamab in a high-grade B-cell lymphoma model, with plans to initiate a Phase 1 clinical trial combination cohort in 2026.

12/06/2025, 8:05 AM • GlobeNewswire

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Arvinas will present multiple research abstracts about vepdegestrant, an investigational drug for estrogen receptor positive breast cancer, at the San Antonio Breast Cancer Symposium in December 2025. The drug is being co-developed with Pfizer and is currently under FDA review.

11/24/2025, 7:00 AM • GlobeNewswire

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Arvinas will present preclinical data for ARV-393, a PROTAC BCL6 degrader targeting non-Hodgkin lymphoma, at the 2025 ASH Annual Meeting in Orlando, Florida.

11/03/2025, 4:00 PM • GlobeNewswire

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Arvinas presented promising preclinical data for ARV-806, a targeted protein degradation drug designed to address KRAS G12D mutations in cancers like pancreatic, colorectal, and lung cancer, demonstrating robust protein degradation and potential therapeutic benefits.

10/24/2025, 4:00 PM • GlobeNewswire

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Arvinas will present preclinical data for ARV-806, a novel PROTAC degrader targeting mutant KRAS G12D, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

10/22/2025, 4:00 PM • GlobeNewswire

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Arvinas will present new clinical data for vepdegestrant, an investigational PROTAC estrogen receptor degrader, at the 2025 ESMO Congress, highlighting patient-reported outcomes and potential treatments for ER+/HER2- breast cancer.

10/13/2025, 7:00 AM • GlobeNewswire

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

Arvinas announced positive Phase 1 clinical trial results for ARV-102, an investigational drug targeting LRRK2 protein in Parkinson's disease. The drug demonstrated dose-dependent brain penetration, reduced protein levels, and showed promising biomarker changes in healthy volunteers and Parkinson's patients.

10/05/2025, 2:00 PM • GlobeNewswire